BORTEZOMIB (VELCADE)
Showing 1 - 25 of 910
Waldenstrom's Macroglobulinemia Trial in Houston (Bortezomib, Rituximab, Valacyclovir)
Active, not recruiting
- Waldenstrom's Macroglobulinemia
- Bortezomib
- +2 more
-
Houston, TexasUniversity of Texas MD Anderson Cancer Center
Dec 5, 2022
Diffuse Large B Cell Lymphoma Trial in Berlin (Ibrutinib and Bortezomib + R-CHOP)
Active, not recruiting
- Diffuse Large B Cell Lymphoma
- Ibrutinib and Bortezomib + R-CHOP
-
Berlin, GermanyCharité - Universitätsmedizin Berlin, Hematology, Oncology and T
Aug 10, 2022
Plasma Cell Myeloma Trial in Atlanta (Bortezomib, Daratumumab, Dexamethasone)
Active, not recruiting
- Plasma Cell Myeloma
- Bortezomib
- +3 more
-
Atlanta, GeorgiaEmory University Hospital/Winship Cancer Institute
Jan 10, 2023
Primary Systemic Amyloidosis, Light Chain Deposition Disease Trial in United States (drug, genetic, other, procedure)
Active, not recruiting
- Primary Systemic Amyloidosis
- Light Chain Deposition Disease
- bortezomib
- +6 more
-
Denver, Colorado
- +6 more
Aug 24, 2022
Multiple Myeloma Trial in Atlanta (Bortezomib, Lenalidomide, Dexamethasone)
Completed
- Multiple Myeloma
- Bortezomib
- +3 more
-
Atlanta, GeorgiaEmory University Winship Cancer Institute
Nov 1, 2021
Solid Tumor, Urethral Cancer Trial in Houston (Bortezomib, Gemcitabine, Doxorubicin)
Active, not recruiting
- Solid Tumor
- Urethral Cancer
- Bortezomib
- +2 more
-
Houston, TexasUniversity of Texas MD Anderson Cancer Center
Sep 22, 2022
Multiple Myeloma Trial in Torino (velcade subcutaneous melphalan prednisone, velcade cyclophosphamide prednisone, velcade
Active, not recruiting
- Multiple Myeloma
- velcade subcutaneous melphalan prednisone
- +2 more
-
Torino, ItalyA.O.U. Città della Salute e della Scienza di Torino - SC Ematolo
Mar 24, 2022
Multiple Myeloma Trial in Saint Louis (Isatuximab, Bortezomib, Dexamethasone)
Recruiting
- Multiple Myeloma
- Isatuximab
- +2 more
-
Saint Louis, MissouriWashington University School of Medicine
Apr 4, 2022
Multiple Myeloma, High-Risk Cancer Trial in Montreal (Bortezomib following nonmyeloablative allogeneic transplant)
Active, not recruiting
- Multiple Myeloma
- High-Risk Cancer
- Bortezomib following nonmyeloablative allogeneic transplant
-
Montreal, Quebec, CanadaHôpital Maisonneuve-Rosemont
Aug 22, 2022
Hodgkin's Lymphoma, Lymphoma, Non-Hodgkin Trial in Ann Arbor (Bortezomib, Ruxolitinib)
Completed
- Hodgkin's Lymphoma
- Lymphoma, Non-Hodgkin
-
Ann Arbor, MichiganUniversity of Michgan Comprehensive Cancer Center
Dec 3, 2021
Light Chain Deposition Disease, Primary Systemic Amyloidosis Trial in Canada, United States (pomalidomide, bortezomib,
Active, not recruiting
- Light Chain Deposition Disease
- Primary Systemic Amyloidosis
- pomalidomide
- +3 more
-
Denver, Colorado
- +4 more
Jan 20, 2023
Recurrent Plasma Cell Myeloma, Refractory Plasma Cell Myeloma Trial in Rochester (Bortezomib, Metformin Hydrochloride,
Active, not recruiting
- Recurrent Plasma Cell Myeloma
- Refractory Plasma Cell Myeloma
- Bortezomib
- +2 more
-
Jacksonville, Florida
- +1 more
Jan 5, 2023
Multiple Myeloma, Auto Stem Cell Transplant Trial in Hackensack (Bortezomib)
Active, not recruiting
- Multiple Myeloma
- Auto Stem Cell Transplant
-
Hackensack, New JerseyJohn Theurer Cancer Center @ Hackensack University Medical Cente
Dec 23, 2022
Multiple Myeloma Based on Multi-omics
Enrolling by invitation
- Multiple Myeloma
- Bortezomib
-
Beijing, ChinaBeijng Chao Yang Hospital
Apr 21, 2022
Lymphoma, Mantle Cell, Mantle Cell Lymphoma Trial run by the NCI (Rituximab (R), EPOCH, Bortezomib (B))
Active, not recruiting
- Lymphoma, Mantle Cell
- Mantle Cell Lymphoma
- Rituximab (R)
- +4 more
-
Bethesda, MarylandNational Institutes of Health Clinical Center, 9000 Rockville Pi
Sep 21, 2021
Antibody-mediated Rejection Trial in Tehran (Bortezomib)
Recruiting
- Antibody-mediated Rejection
-
Tehran, Iran, Islamic Republic ofSBMU
Jan 27, 2022
Waldenstrom's Macroglobulinemia Trial in Boston (Everolimus, Rituximab, Bortezomib)
Terminated
- Waldenstrom's Macroglobulinemia
- Everolimus
- +2 more
-
Boston, MassachusettsDana-Farber Cancer Institute
Apr 22, 2021
Multiple Myeloma Trial in Hackensack (Fludarabine monophosphate, melphalan, Bortezomib)
Completed
- Multiple Myeloma
- Fludarabine monophosphate, melphalan, Bortezomib
-
Hackensack, New JerseyJohn Theurer Cancer Center at Hackensack University Medical Cent
Apr 29, 2022
High-risk Smoldering Multiple Myeloma, Multiple Myeloma Trial in Boston (Daratumumab, Bortezomib, Lenalidomide)
Recruiting
- High-risk Smoldering Multiple Myeloma
- Multiple Myeloma
- Daratumumab
- +3 more
-
Boston, Massachusetts
- +1 more
Oct 18, 2021
Multiple Myeloma, Refractory Multiple Myeloma Trial (procedure, drug, radiation)
Withdrawn
- Multiple Myeloma
- Refractory Multiple Myeloma
- nonmyeloablative allogeneic hematopoietic stem cell transplantation
- +7 more
- (no location specified)
Jan 4, 2023
Multiple Myeloma Trial in Worldwide (Daratumumab, velcade, Lenalidomide)
Active, not recruiting
- Multiple Myeloma
- Daratumumab
- +3 more
-
Melbourne, Australia
- +12 more
Aug 25, 2021
Lymphoma Trial in Duarte, South Pasadena (biological, drug, other)
Active, not recruiting
- Lymphoma
- rituximab
- +3 more
-
Duarte, California
- +1 more
Feb 28, 2022